Equities analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to announce earnings of ($0.16) per share for the current quarter, Zacks reports. Two analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.18). BioCryst Pharmaceuticals posted earnings per share of ($0.19) during the same quarter last year, which suggests a positive year over year growth rate of 15.8%. The company is expected to issue its next quarterly earnings report on Thursday, May 3rd.
On average, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($0.79) per share for the current financial year, with EPS estimates ranging from ($0.87) to ($0.68). For the next year, analysts forecast that the business will report earnings of ($0.78) per share, with EPS estimates ranging from ($0.83) to ($0.72). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.06). The company had revenue of $3.89 million during the quarter, compared to analyst estimates of $6.07 million. BioCryst Pharmaceuticals had a negative net margin of 261.18% and a negative return on equity of 106.53%. The firm’s quarterly revenue was down 56.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) EPS.
BioCryst Pharmaceuticals stock traded down $0.12 during trading hours on Monday, hitting $4.65. The company had a trading volume of 429,372 shares, compared to its average volume of 1,216,445. The firm has a market cap of $470.35, a PE ratio of -5.96 and a beta of 2.71. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.68 and a current ratio of 1.68. BioCryst Pharmaceuticals has a fifty-two week low of $3.95 and a fifty-two week high of $8.80.
A number of hedge funds have recently bought and sold shares of BCRX. Los Angeles Capital Management & Equity Research Inc. bought a new stake in BioCryst Pharmaceuticals in the third quarter worth approximately $132,000. SG Americas Securities LLC grew its position in BioCryst Pharmaceuticals by 98.6% in the third quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 13,402 shares in the last quarter. Wells Fargo & Company MN grew its position in BioCryst Pharmaceuticals by 50.7% in the third quarter. Wells Fargo & Company MN now owns 96,671 shares of the biotechnology company’s stock worth $507,000 after acquiring an additional 32,530 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in BioCryst Pharmaceuticals by 4.0% in the third quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock worth $1,678,000 after acquiring an additional 12,267 shares in the last quarter. Finally, VHCP Management II LLC grew its position in BioCryst Pharmaceuticals by 27.9% in the third quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock worth $16,587,000 after acquiring an additional 690,290 shares in the last quarter. 91.54% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “-$0.16 Earnings Per Share Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter” was first posted by WKRB News and is owned by of WKRB News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.wkrb13.com/2018/04/02/0-16-earnings-per-share-expected-for-biocryst-pharmaceuticals-inc-bcrx-this-quarter.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.